Charter Trust Co. raised its stake in shares of Allergan PLC. (NYSE:AGN) by 48.1% during the second quarter, Holdings Channel reports. The firm owned 1,321 shares of the company’s stock after buying an additional 429 shares during the period. Charter Trust Co.’s holdings in Allergan PLC. were worth $321,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of AGN. Telemus Capital LLC increased its stake in Allergan PLC. by 208.1% in the first quarter. Telemus Capital LLC now owns 21,012 shares of the company’s stock worth $5,020,000 after buying an additional 14,193 shares during the last quarter. Farmers & Merchants Investments Inc. increased its stake in Allergan PLC. by 89.9% in the first quarter. Farmers & Merchants Investments Inc. now owns 29,073 shares of the company’s stock worth $6,946,000 after buying an additional 13,765 shares during the last quarter. Reliance Trust Co. of Delaware increased its stake in Allergan PLC. by 1.2% in the first quarter. Reliance Trust Co. of Delaware now owns 13,292 shares of the company’s stock worth $3,176,000 after buying an additional 159 shares during the last quarter. Reilly Financial Advisors LLC increased its stake in Allergan PLC. by 0.7% in the first quarter. Reilly Financial Advisors LLC now owns 44,392 shares of the company’s stock worth $10,606,000 after buying an additional 299 shares during the last quarter. Finally, OLD Second National Bank of Aurora increased its stake in Allergan PLC. by 97.3% in the first quarter. OLD Second National Bank of Aurora now owns 5,298 shares of the company’s stock worth $1,266,000 after buying an additional 2,613 shares during the last quarter. Institutional investors own 83.63% of the company’s stock.

Allergan PLC. (AGN) traded down 0.213% during trading on Tuesday, reaching $232.145. 594,744 shares of the company’s stock were exchanged. The company has a market capitalization of $77.61 billion, a PE ratio of 7.073 and a beta of 1.16. The company’s 50-day moving average is $245.54 and its 200-day moving average is $238.65. Allergan PLC. has a 1-year low of $184.50 and a 1-year high of $256.80.

Allergan PLC. (NYSE:AGN) last issued its earnings results on Thursday, August 3rd. The company reported $4.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.95 by $0.07. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. The company had revenue of $4.01 billion for the quarter, compared to the consensus estimate of $3.95 billion. During the same quarter last year, the company earned $3.35 EPS. The firm’s quarterly revenue was up 8.8% on a year-over-year basis. Equities research analysts expect that Allergan PLC. will post $16.27 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 15th. Shareholders of record on Friday, August 18th will be paid a $0.70 dividend. This represents a $2.80 dividend on an annualized basis and a yield of 1.20%. The ex-dividend date of this dividend is Wednesday, August 16th. Allergan PLC.’s payout ratio is 9.95%.

ILLEGAL ACTIVITY WARNING: This piece of content was posted by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark laws. The legal version of this piece of content can be read at https://www.watchlistnews.com/charter-trust-co-has-321000-position-in-allergan-plc-agn/1490756.html.

AGN has been the subject of a number of research analyst reports. Cowen and Company set a $400.00 price objective on Allergan PLC. and gave the stock a “buy” rating in a report on Thursday, June 8th. Sanford C. Bernstein restated an “outperform” rating on shares of Allergan PLC. in a report on Thursday, May 25th. Mizuho dropped their price objective on Allergan PLC. from $275.00 to $267.00 and set a “buy” rating for the company in a report on Friday, June 9th. Cantor Fitzgerald initiated coverage on Allergan PLC. in a report on Friday, June 16th. They set a “neutral” rating and a $231.00 price objective for the company. Finally, Zacks Investment Research upgraded Allergan PLC. from a “hold” rating to a “buy” rating and set a $270.00 price objective for the company in a report on Tuesday, July 11th. Eight investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $275.49.

In other Allergan PLC. news, Director Nesli Basgoz sold 1,889 shares of Allergan PLC. stock in a transaction that occurred on Thursday, May 18th. The stock was sold at an average price of $220.45, for a total value of $416,430.05. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 0.36% of the company’s stock.

Allergan PLC. Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with Analyst Ratings Network's FREE daily email newsletter.